MX2011006773A - Biomarcador. - Google Patents

Biomarcador.

Info

Publication number
MX2011006773A
MX2011006773A MX2011006773A MX2011006773A MX2011006773A MX 2011006773 A MX2011006773 A MX 2011006773A MX 2011006773 A MX2011006773 A MX 2011006773A MX 2011006773 A MX2011006773 A MX 2011006773A MX 2011006773 A MX2011006773 A MX 2011006773A
Authority
MX
Mexico
Prior art keywords
acid sequence
biomarkers
lung cancer
biomarker
bladder cancer
Prior art date
Application number
MX2011006773A
Other languages
English (en)
Other versions
MX343251B (es
Inventor
Richard Morgan
Hardev S Pandha
Original Assignee
Univ Surrey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Surrey filed Critical Univ Surrey
Publication of MX2011006773A publication Critical patent/MX2011006773A/es
Publication of MX343251B publication Critical patent/MX343251B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen biomarcadores específicos de cáncer de vejiga y biomarcadores específicos de cáncer de pulmón que comprenden la secuencia de ácido nucleico del gene Engrailed-2 (EN2) o la secuencia de aminoácido de la proteína EN2 codificada. También se describen usos de los biomarcadores en el tratamiento, diagnóstico, supervisión y formación de imagen de cáncer de vejiga o cáncer de pulmón.
MX2011006773A 2008-12-23 2009-12-21 Biomarcador. MX343251B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0823445.2A GB0823445D0 (en) 2008-12-23 2008-12-23 Biomarker
PCT/GB2009/002926 WO2010073001A1 (en) 2008-12-23 2009-12-21 Biomarker

Publications (2)

Publication Number Publication Date
MX2011006773A true MX2011006773A (es) 2011-08-03
MX343251B MX343251B (es) 2016-10-31

Family

ID=40344114

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011006773A MX343251B (es) 2008-12-23 2009-12-21 Biomarcador.

Country Status (15)

Country Link
US (1) US9624548B2 (es)
EP (1) EP2382327B1 (es)
JP (1) JP5947040B2 (es)
CN (1) CN102301006B (es)
AU (1) AU2009332712B2 (es)
BR (1) BRPI0923525A2 (es)
CA (1) CA2747760C (es)
ES (1) ES2725150T3 (es)
GB (1) GB0823445D0 (es)
IL (1) IL213510A (es)
MX (1) MX343251B (es)
NZ (1) NZ593392A (es)
RU (1) RU2573925C2 (es)
WO (1) WO2010073001A1 (es)
ZA (1) ZA201105184B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
JP5940093B2 (ja) 2011-01-19 2016-06-29 カンタージア アクチエボラーグ 抗ｉｌ−１ｒａｐ抗体及びヒトを処置するためのそれらの使用
US11371941B2 (en) * 2016-07-04 2022-06-28 Celltool Gmbh Device and method for the determination of transfection
KR101923199B1 (ko) 2018-04-25 2018-11-28 주식회사 무진메디 펩스타틴 a를 함유하는 소변 내 en2 진단용 조성물
JPWO2021066038A1 (es) 2019-10-02 2021-04-08

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2469089A1 (en) 2003-07-08 2005-01-08 Institut De Recherches Cliniques De Montreal En-2 gene, disgnostic and therapeutic uses thereof
EP2295601A1 (en) * 2005-02-10 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
GB0625321D0 (en) 2006-12-19 2007-01-24 Univ Surrey Cancer biomarker
EP2258871B1 (en) * 2007-01-19 2014-05-14 Epigenomics AG Methods and nucleic acids for analyses of cell proliferative disorders
US20110003292A1 (en) 2007-12-11 2011-01-06 Dimo Dietrich Methods and nucleic acids for analyses of cell proliferative disorders

Also Published As

Publication number Publication date
JP5947040B2 (ja) 2016-07-06
US20120020888A1 (en) 2012-01-26
CA2747760A1 (en) 2010-07-01
ZA201105184B (en) 2012-02-29
EP2382327A1 (en) 2011-11-02
IL213510A (en) 2016-04-21
IL213510A0 (en) 2011-07-31
US9624548B2 (en) 2017-04-18
CN102301006B (zh) 2015-07-15
RU2011130795A (ru) 2013-01-27
AU2009332712A1 (en) 2011-07-07
RU2573925C2 (ru) 2016-01-27
GB0823445D0 (en) 2009-01-28
ES2725150T3 (es) 2019-09-19
CN102301006A (zh) 2011-12-28
MX343251B (es) 2016-10-31
BRPI0923525A2 (pt) 2020-08-11
EP2382327B1 (en) 2019-02-13
JP2012513584A (ja) 2012-06-14
NZ593392A (en) 2013-05-31
WO2010073001A1 (en) 2010-07-01
AU2009332712B2 (en) 2015-05-28
CA2747760C (en) 2020-01-21

Similar Documents

Publication Publication Date Title
EP1888786A4 (en) USE FREE CIRCULATIVE DNA FOR THE DIAGNOSIS, FORECAST AND TREATMENT OF CANCER
WO2006110599A3 (en) Cacna1e in cancer diagnosis, detection and treatment
IN2012DN04381A (es)
WO2012054639A3 (en) Nmr systems and methods for the rapid detection of analytes
WO2008061213A3 (en) Genetic variations associated with tumors
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2007041245A3 (en) Biomarkers for multiple sclerosis and methods of use thereof
WO2009153775A3 (en) Methods for distinguishing between specific types of lung cancers
WO2010019921A3 (en) Biomarkers for diagnosis and treatment of chronic lymphocytic leukemia
WO2005039382A3 (en) Prediction of likelihood of cancer recurrence
EP2502628A3 (en) Polynucleotides and polypeptide sequences involved in cancer
EP2611941A4 (en) GENESIS OF CANCER DIAGNOSIS AND PROGNOSIS
IL190796A (en) Composition containing nucleic acid encoded by anti-osteoclastogenic protein
WO2006110594A3 (en) Sema4d in cancer diagnosis, detection and treatment
WO2009094647A3 (en) P53 biomarkers
WO2008073899A3 (en) Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
WO2011073629A3 (en) Cancer diagnosis and treatment
EA200970891A1 (ru) Генетические варианты chr2 и chr16 в качестве маркеров для применения при оценке риска, диагностировании, прогнозировании и лечении рака молочной железы
WO2011015944A3 (en) Use of free dna as an early predictor of severity in acute pancreatitis
WO2008103971A3 (en) Prostate cancer survival and recurrence
MX2011006773A (es) Biomarcador.
WO2010132370A3 (en) Soluble tlt-1 for the treatment and diagnosis of sepsis
WO2017027391A3 (en) Genetic abnormalities in plasma cell dyscrasias
WO2009074328A3 (en) Methods and nucleic acids for analyses of lung carcinoma
WO2010028373A3 (en) Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients

Legal Events

Date Code Title Description
FG Grant or registration